Medtronic (MDT) Q4 Fiscal 2026 Earnings Preview: Key Expectations Ahead of the June 3 Report
Key Takeaways
- Medtronic is set to report fourth-quarter and full fiscal year 2026 results on June 3, 2026.
- Analyst consensus estimates call for Q4 revenue near $9.62 billion and non-GAAP EPS of approximately $1.55.
- Full-year fiscal 2026 non-GAAP EPS guidance from prior updates centers in the $5.50 to $5.54 range.
- Investors will monitor revenue growth across Medtronic’s major segments, including cardiovascular and diabetes.
- Historical patterns show the company has frequently met or slightly exceeded revenue targets in recent quarters.
- Market focus remains on organic growth trends and any updates to fiscal 2027 outlook.
Earnings Context and Why It Matters
Medtronic’s fourth-quarter results will close fiscal year 2026, which ends April 24, 2026. The report follows a strong third quarter that delivered the highest enterprise revenue growth in ten quarters. Investors watch these results closely because Medtronic operates in the competitive healthcare technology sector, where demand for medical devices and consistent revenue growth influence valuation. The earnings release also provides the first full-year view after earlier guidance adjustments, helping set expectations for the new fiscal year beginning in late April 2026.
Earnings Expectations
Wall Street consensus anticipates fourth-quarter revenue of about $9.62 billion, representing roughly 8% year-over-year growth. Non-GAAP earnings per share estimates center near $1.55. For the full fiscal year 2026, earlier company guidance pointed to organic revenue growth of approximately 5% and diluted non-GAAP EPS in the $5.50 to $5.54 range, excluding certain tariff impacts. Key metrics under scrutiny include segment revenue trends, gross margins, and performance in high-growth areas such as diabetes and cardiovascular platforms. Past quarters have shown Medtronic frequently meeting or slightly exceeding revenue targets while delivering steady earnings results. To compare MDT against peers, I also checked this using Tickeron’s AI Screener.
Market Reaction and Investor Sentiment
Sentiment heading into the report remains constructive following Medtronic’s recent revenue growth acceleration. Analysts note steady demand across core segments and limited surprises in prior quarters. Key risk factors include foreign currency movements, potential tariff effects, and any commentary on competitive pressures in the diabetes or neuromodulation markets. Pre-earnings positioning typically focuses on whether results will support the company’s full-year targets and provide positive signals for fiscal 2027.
Forward Outlook and Key Factors to Monitor
Following the June 3 release, attention will shift to any updates on fiscal 2027 guidance and segment-specific trends. Investors will examine revenue contributions from cardiovascular, medical-surgical, neuroscience, and diabetes businesses for signs of sustained momentum.
Cost management, gross margin performance, and foreign exchange impacts will also feature prominently. Broader industry dynamics, such as hospital capital spending and regulatory developments, could influence the tone of management commentary.
Any discussion of new product launches or pipeline progress in high-growth areas will help frame expectations for the year ahead. The report may clarify how recent acquisitions and operational initiatives are contributing to overall results.
Enhancing Analysis with AI Tools
In my research process, I frequently turn to Tickeron’s AI Screener to filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. It allows users to scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. This helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
MDT in +3.90% Uptrend, rising for three consecutive days on August 19, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where MDT advanced for three days, in of 313 cases, the price rose further within the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on July 27, 2026. You may want to consider a long position or call options on MDT as a result. In of 80 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for MDT just turned positive on July 27, 2026. Looking at past instances where MDT's MACD turned positive, the stock continued to rise in of 45 cases over the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 212 cases where MDT Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The 10-day RSI Indicator for MDT moved out of overbought territory on August 20, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 24 similar instances where the indicator moved out of overbought territory. In of the 24 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 9 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MDT declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
MDT broke above its upper Bollinger Band on August 11, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.415) is normal, around the industry mean (11.035). P/E Ratio (25.027) is within average values for comparable stocks, (70.949). Projected Growth (PEG Ratio) (1.843) is also within normal values, averaging (4.006). MDT has a moderately high Dividend Yield (0.031) as compared to the industry average of (0.017). P/S Ratio (3.307) is also within normal values, averaging (34.463).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. MDT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MDT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of medical technology services
Industry MedicalNursingServices
Advertisement